Potential Dapagliflozin Benefit Post-MI Is Not a ‘Mandate’
PHILADELPHIA — Giving the SGLT-2 inhibitor dapagliflozin (Farxiga) to patients with acute myocardial infarction (MI) and impaired left ventricular systolic ...
PHILADELPHIA — Giving the SGLT-2 inhibitor dapagliflozin (Farxiga) to patients with acute myocardial infarction (MI) and impaired left ventricular systolic ...
AMSTERDAM — Adults with type 2 diabetes who were on a sodium-glucose cotransporter 2 (SGLT2) inhibitor at the time of ...
Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. A new meta-analysis has shown that ...
Dapagliflozin (Farxiga) appears to be no more effective than the "thiazide-like" diuretic metolazone at improving pulmonary congestion and fluid status ...
Sotagliflozin, a novel agent that inhibits sodium-glucose cotransporter (SGLT) 1 as well as SGLT2, received marketing approval from the US ...
The European Commission (EC) has expanded the indication for dapagliflozin (Forxiga) to include heart failure (HF) across the full spectrum ...
© Pharma News Hubb All rights reserved.
Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.
© 2022 Pharma News Hubb All rights reserved.